SCHEMBL922157

SCHEMBL922157

Cc1ccc(C2=NN=C(N)/C2=N/Nc2ccccc2)cc1[N+](=O)[O-]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.43
MAPT P10636 8/20 0.43
SMN1; SMN2 Q16637 8/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
LMNA P02545 3/20 0.43
CYP3A4 P08684 2/20 0.43
TSHR P16473 2/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.43
CYP1A2 P05177 2/20 0.41
ALOX12 P18054 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
POLB P06746 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL922159 1.00 ALDH1A1 (0.43) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL922198 0.87 MAPT (0.43) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL922197 0.87 MAPT (0.43) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL922404 0.84 ALDH1A1 (0.36) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL922402 0.84 ALDH1A1 (0.36) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL924419 0.82 MAPT (0.46) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL924420 0.82 MAPT (0.46) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL922593 0.81 ABCG2 (0.43) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL922591 0.81 ABCG2 (0.43) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL923870 0.81 DEPTOR (0.34) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 US disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 ALDH1A1 1614/4885MAPT 4573/4885SMN1; SMN2 4161/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 ALDH1A1 1614/4885MAPT 4573/4885SMN1; SMN2 4161/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC ALDH1A1 3393/4885MAPT 4000/4885SMN1; SMN2 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.